Naltrexonum [Inn-Latin] en es it fr

Naltrexonum [Inn-Latin] Brand names, Naltrexonum [Inn-Latin] Analogs

Naltrexonum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Naltrexonum [Inn-Latin] Chemical_Formula


Naltrexonum [Inn-Latin] RX_link

Naltrexonum [Inn-Latin] fda sheet

Naltrexonum_[Inn-Latin] FDA

Naltrexonum [Inn-Latin] msds (material safety sheet)

Naltrexonum_[Inn-Latin] MSDS

Naltrexonum [Inn-Latin] Synthesis Reference

No information avaliable

Naltrexonum [Inn-Latin] Molecular Weight

341.401 g/mol

Naltrexonum [Inn-Latin] Melting Point

169-170 oC (274-276 oC for hydrochloride salt)

Naltrexonum [Inn-Latin] H2O Solubility

100 mg/mL (as hydrochloride salt)

Naltrexonum [Inn-Latin] State


Naltrexonum [Inn-Latin] LogP

1.692 (1.92 by expt)

Naltrexonum [Inn-Latin] Dosage Forms

Tablet (scored, film-coated, 50 mg)

Naltrexonum [Inn-Latin] Indication

For use in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids.

Naltrexonum [Inn-Latin] Pharmacology

Naltrexone, a pure opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone is indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. It markedly attenuates or completely blocks, reversibly, the subjective effects of intravenously administered opioids. When co-administered with morphine, on a chronic basis, naltrexone blocks the physical dependence to morphine, heroin and other opioids. In subjects physically dependent on opioids, naltrexone will precipitate withdrawal symptomatology.

Naltrexonum [Inn-Latin] Absorption

Although well absorbed orally, naltrexone is subject to significant first pass metabolism with oral bioavailability estimates ranging from 5 to 40%.

Naltrexonum [Inn-Latin] side effects and Toxicity

In the mouse, rat and guinea pig, the oral LD50s were 1,100-1,550 mg/kg; 1,450 mg/kg; and 1,490 mg/kg; respectively. High doses of naltrexone (generally ≥1,000 mg/kg) produce salivation, depression/reduced activity, tremors, and convulsions.

Naltrexonum [Inn-Latin] Patient Information

It is recommended that the prescribing physician relate the following information to patients being treated with REVIA:

You have been prescribed REVIA as part of the comprehensive treatment for your alcoholism or drug dependence. You should carry identification to alert medical personnel to the fact that you are taking REVIA. A REVIA medication card may be obtained from your physician and can be used for this purpose. Carrying the identification card should help to ensure that you can obtain adequate treatment in an emergency. If you require medical treatment, be sure to tell the treating physician that you are receiving REVIA therapy.

You should take REVIA as directed by your physician. If you attempt to self-administer heroin or any other opiate drug, in small doses while on REVIA, you will not perceive any effect. Most important, however, if you attempt to self-administer large doses of heroin or any other opioid while on REVIA, you may die or sustain serious injury, including coma.

REVIA is well-tolerated in the recommended doses, but may cause liver injury when taken in excess or in people who develop liver disease from other causes. If you develop abdominal pain lasting more than a few days, white bowel movements, dark urine, or yellowing of your eyes, you should stop taking REVIA immediately and see your doctor as soon as possible.

Naltrexonum [Inn-Latin] Organisms Affected

Humans and other mammals